Incyte is preparing to take an oral JAK inhibitor into phase 3 trials for the skin depigmentation disease vitiligo, after reporting mid-stage data showing efficacy in patients with facial and full ...

Saphnelo (anifrolumab) is the first biologic drug for SLE to be approved in Europe that is not restricted to patients with a high degree of disease activity, according to AZ, which also notes it ...

Discover a study that investigates spesolimab, a monoclonal antibody that has been approved as the first GPP-specific therapy ...

Patients with radiographic axial spondyloarthritis who receive ixekizumab biweekly demonstrate lower sacroiliac joint erosion and increased the backfill of new tissue through 52 weeks, according ...

Objective Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease characterised by variable treatment responses. We investigated the transcriptional landscape associated with treatment ...